Ndwm LLC Makes New $222,000 Investment in Eli Lilly and Company (NYSE:LLY)

Ndwm LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY) during the first quarter, Holdings Channel reports. The institutional investor acquired 286 shares of the company’s stock, valued at approximately $222,000.

Several other institutional investors have also recently modified their holdings of the company. Versant Capital Management Inc grew its position in shares of Eli Lilly and Company by 1.8% in the first quarter. Versant Capital Management Inc now owns 736 shares of the company’s stock valued at $573,000 after purchasing an additional 13 shares in the last quarter. Moseley Investment Management Inc. raised its holdings in shares of Eli Lilly and Company by 0.4% during the 1st quarter. Moseley Investment Management Inc. now owns 3,890 shares of the company’s stock worth $3,027,000 after acquiring an additional 14 shares during the period. CGN Advisors LLC boosted its position in shares of Eli Lilly and Company by 1.4% during the 1st quarter. CGN Advisors LLC now owns 1,001 shares of the company’s stock valued at $779,000 after acquiring an additional 14 shares during the last quarter. Buckhead Capital Management LLC grew its holdings in shares of Eli Lilly and Company by 0.7% in the fourth quarter. Buckhead Capital Management LLC now owns 2,104 shares of the company’s stock valued at $1,226,000 after purchasing an additional 15 shares during the period. Finally, Levin Capital Strategies L.P. increased its position in Eli Lilly and Company by 3.8% during the fourth quarter. Levin Capital Strategies L.P. now owns 415 shares of the company’s stock worth $242,000 after purchasing an additional 15 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday. The Goldman Sachs Group increased their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Argus upped their price target on Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research note on Tuesday, May 14th. BMO Capital Markets reissued an “outperform” rating and set a $1,001.00 target price on shares of Eli Lilly and Company in a research note on Wednesday. Finally, JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $812.72.

Insider Buying and Selling

In other news, major shareholder Lilly Endowment Inc sold 194,978 shares of the firm’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $885.91, for a total transaction of $172,732,959.98. Following the sale, the insider now owns 97,583,810 shares in the company, valued at $86,450,473,117.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares in the company, valued at approximately $5,842,821.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 194,978 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $885.91, for a total transaction of $172,732,959.98. Following the completion of the transaction, the insider now owns 97,583,810 shares in the company, valued at approximately $86,450,473,117.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 858,742 shares of company stock worth $735,573,781. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Trading Down 0.9 %

Shares of LLY opened at $898.10 on Friday. Eli Lilly and Company has a twelve month low of $434.34 and a twelve month high of $918.50. The firm has a market capitalization of $853.56 billion, a P/E ratio of 132.27, a PEG ratio of 1.96 and a beta of 0.41. The firm’s 50-day moving average is $828.07 and its two-hundred day moving average is $747.74. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter last year, the business posted $1.62 earnings per share. The business’s revenue for the quarter was up 26.0% on a year-over-year basis. On average, research analysts predict that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be given a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.58%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.